990-P: Use of Glucose-Lowering Agents According to Cardiovascular Risk Factors in People with T2D and with or without CVD in the CAPTURE Study

Objective: This CAPTURE post-hoc analysis identified patterns in the use of selected glucose-lowering agents (GLA) in people with T2D with or without CVD and by CVD risk factor prevalence. Methods: CAPTURE was a cross-sectional, observational study in people with T2D across 13 countries. Participant information was collected during a single routine clinical visit in a primary/specialist setting between Dec 1, 2018 and Sep 31, 2019. Data were analyzed descriptively. Results: Of 9823 participants, 3582 had a history of CVD (CVD group) and 6241 had no history of CVD (NoCVD group). Regardless of CVD status, use of GLA was more common in those who were males, aged 55-≤75 yrs, or who had a diabetes duration >10 yrs, HbA1c >7-60 ml/min/1.73m2. Newer agents (GLP-1 RAs and SGLT2is) were less prescribed versus insulins and sulfonylureas (SUs). Compared with NoCVD, use of newer agents was lower in people from CVD group who were aged